Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02888054 · ClinicalTrials.gov registry record · Phase 1
Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence
A Phase 1 study, sponsored by Ardea Biosciences.
- Completed
- Registry status
- Phase 1
- Development phase
- 28
- Enrollment target
NCT02888054 is a Phase 1 study that has completed, run by Ardea Biosciences. The registered enrollment target is 28 participants.
The verdict
NCT02888054, a Phase 1 study, has completed, sponsored by Ardea Biosciences.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 28 participants
- Enrollment target
Study Summary
This study will assess the bioequivalence (BE) of Lesinurad/Allopurinol Fixed-Dose Combination (FDC) Tablets and Coadministered Lesinurad and Allopurinol Tablets in Fed Healthy Adult Subjects
Interventions
- DRUG lesinurad 200 mg
- DRUG allopurinol 300 mg
- DRUG lesinurad/allopurinol 200/300 FDC tablet
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 28 participants |
| Start Date | 2016-08-30 |
| Est. Completion | 2017-02-01 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02888054
The ClinicalTrials.gov registry entry for NCT02888054 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 28 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ardea Biosciences, which has 32 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which lesinurad 200 mg is the first listed.
NCT02888054 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02888054 about?
NCT02888054 is a clinical study titled "Lesinurad/Allopurinol 200/300 FDC Tablets Bioequivalence". This study will assess the bioequivalence (BE) of Lesinurad/Allopurinol Fixed-Dose Combination (FDC) Tablets and Coadministered Lesinurad and Allopurinol Tablets in Fed Healthy Adult Subjects
What is the current status of trial NCT02888054?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 28 participants. The study started on 2016-08-30. Estimated completion is 2017-02-01.
What interventions are being tested in trial NCT02888054?
The interventions under investigation include: lesinurad 200 mg (DRUG), allopurinol 300 mg (DRUG), lesinurad/allopurinol 200/300 FDC tablet (DRUG).
Who is sponsoring clinical trial NCT02888054?
This trial is sponsored by Ardea Biosciences, which has 32 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.